Biography for Emily Mullin
Emily Mullin, Associate Editor
Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the Baltimore Business Journal, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to The Maryland Daily Record, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in Nephrology Times, Columbus Business First and the Cincinnati Business Courier. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at email@example.com and follow her on Twitter at @EmilyMFierce.
- Contact Emily
- Follow Emily on Google+
Articles by Emily Mullin
Despite conventional wisdom, parents are not necessarily more likely to vaccinate their children when the risk of catching a disease is heightened, according to a new study.
Vaccine sales can only grow as much as patient adherence to immunization recommendations allows, but Merck is rolling out a new initiative that could give its vaccines unit a boost.
As climate change and international travel threaten to heighten the burden of malaria worldwide, a new study reports that a malaria vaccine may soon be on the horizon.
Refrigeration for vaccines is still a major barrier to improving vaccination rates in many parts of the developing world. But a new study by Médecins Sans Frontières shows that some vaccines can be used safely outside the cold chain, underscoring the need for more research on heat-stable vaccines.
Researchers have for the first time established human immune responses to a bacterium responsible for stomach cancer, marking a major step toward a vaccine against the pathogen.
As the death toll from the Ebola virus in West Africa climbs to 135 people, a vaccine to combat the deadly virus remains years out of reach.
Whooping cough is back with a vengeance, and the culprit may be the changing nature of the bacterium that causes the highly infectious disease.
One of three manufacturing sites commissioned by the Department of Health and Human Services to quickly develop and produce flu vaccines in the case of a pandemic is expected to be fully operational by 2017, officials say.
To help countries achieve the maximum impact of new vaccines, the World Health Organization has released new guidance on how to introduce new vaccines in existing immunization programs.
Last year's flu vaccine didn't provide as much coverage as scientists had hoped, and now researchers from Canada's British Columbia Centre for Disease Control think they have discovered the culprit.